


RealRate

PHARMACEUTICAL 2022

Xenon Pharmaceuticals Inc. Rank 69 of 475

🖁 XENON







PHARMACEUTICAL 2022



Xenon Pharmaceuticals Inc. Rank 69 of 475



The relative strengths and weaknesses of Xenon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenon Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 161% points. The greatest weakness of Xenon Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 96%, being 372% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	559,020
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,322
Liabilities, Non-Current	7,652
Other Assets	8,521
Other Compr. Net Income	0
Other Expenses	-6.0
Other Liabilities	0
Other Net Income	105
Property and Equipment	4,466
Research and Development	75,463
Revenues	18,437
Selling, General and Administrative Expense	21,967

Output Variable	Value in 1000 USD
Assets	572,007
Liabilities	21,974
Expenses	97,424
Stockholders Equity	550,033
Net Income	-78,882
Comprehensive Net Income	-78,882
Economic Capital Ratio	96%

